Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Medbright AI Investments Inc MBAIF


Primary Symbol: C.MBAI

MedBright AI Investments Inc. is a capital allocator focused on investing in healthcare technology companies. The Company is engaged in constructing a portfolio of synergistic investments to generate returns for shareholders. The Company is focused on significant near-term and midterm opportunities with potential returns while maintaining a commitment to governance. It is focused on investing... see more

CSE:MBAI - Post Discussion

Medbright AI Investments Inc > 3x the Average Volume Today
View:
Post by MarketMakerss on Feb 21, 2024 2:35pm

3x the Average Volume Today

Boasting almost 3x the average volume today already, MedBright AI (MBAI.c MBAIF) is aiming to drive innovation in healthcare with its focus on a $200 billion dollar healthcare problem of congested waiting rooms.
 
MedMatrix
Focused on the intersection of healthcare and technology to match patient needs with enhanced revenue opportunities, MBAI is the primary shareholder of and is targeting the healthcare waiting room problem with MedMatrix.
 
As detailed in this short introduction video, MedMatrix is an AI-powered data analytics platform and engine that analyzes crucial aspects of healthcare facilities and works alongside healthcare professionals to drastically improve healthcare operations and enhance clinic revenue by 10% at no additional cost to the clinic: https://youtu.be/f3bcx2T_GzQ?si=9CXluAYD43PEDMM9
 
In better aligning physician resources with patient needs, MedMatrix evaluates numerous factors related to a patient's background, clinical interaction history and other factors to predict the resource needs for their upcoming visits and optimize provider schedules, without the need for a new platform or additional training.
 
Recent News
Having closed its previously announced LIFE offering for gross proceeds of ~$1.4M, MBAI is well financed to continue its business development on the heels of its previously expanded offerings for MedMatrix, its AI-powered data analytics platform.
 
Adding onto its previous adoption, Rejuvenation, a prominent dermatology group and leader in advanced dermatological care, has expanded its already established use of MedMatrix to include marketing for cosmetic treatments and clinical trial recruitment and data analysis.
 
This is a significant demonstration of both the substantial scalability and the vast addressable market that is open to MedMatrix and, as MBAI continues to execute on this path, it could mean quick multiples from successfully solving even a small percentage of the addressable market.
 
Notably, Rejuvenation's extensive network includes 8 clinics spread across 3 provinces with a highly skilled team comprising of 21 dermatologists, 5 Mohs surgeons, 2 plastic surgeons, and 13 general practitioners specializing in dermatology.
 
Despite having an mcap of only $22M, MBAI has been able to expand to 14 clinics, including a Yale University-Affiliated Clinic, and is strongly positioned to fix the $200 billion healthcare problem of congested waiting rooms.
 
 
Posted on Behalf of MedBright AI Investments Inc.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities